PPIDT00251
Drug Information
| Name | Secukinumab |
|---|---|
| Sequence | EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYWMNWVRQAPGKGLEWVAAINQDGSEKYYVGSVKGRFTISRDNAKNSLYLQMNSLRVEDTAVYYCVRDYYDILTDYYIHYWYFDLWGRGTLVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKRVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB09029 |
| Type | biotech |
| Indication | Secukinumab is indicated the treatment of moderate to severe plaque psoriasis in patients six years and older who are candidates for systemic therapy or phototherapy.[L39600] In Europe, the drug is used in children and adolescents six to 18 years of age for this indication.[L42280] It is also indicated for the treatment of active psoriatic arthritis (PsA). In the US, it is approved for patients two years of age and older [L39600] while in Europe, it is used alone or in combination with [methotrexate] in patients six years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.[L42280] Secukinumab is also indicated in the treatment of active enthesitis-related arthritis (ERA). In the US, it is approved for patients four year of age and older.[L39600] In Europe, it is used alone or in combination with [methotrexate] in patients six years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.[L42280] In the US, secukinumab is indicated for the treatment of adults with active ankylosing spondylitis, non-radiographic axial spondyloarthritis with objective signs of inflammation, moderate to severe hidradenitis suppurativa.[L48771] |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
150 mg/1mL
|
| Injection | Subcutaneous |
300 mg/2mL
|
| Injection | Subcutaneous |
75 mg/0.5mL
|
| Injection, solution | Parenteral; Subcutaneous |
150 MG
|
| Injection, solution | Parenteral; Subcutaneous |
300 MG
|
| Injection, solution | Parenteral; Subcutaneous |
75 MG
|
| Injection, solution | Subcutaneous |
150 mg
|
| Injection, solution | Subcutaneous |
300 mg
|
| Injection, solution | Subcutaneous |
75 mg
|
| Injection, solution, concentrate | Intravenous |
25 mg/1mL
|
| Powder, for solution | Subcutaneous |
150 mg / mL
|
| Solution | Subcutaneous |
150 mg / mL
|
| Solution | Subcutaneous |
15000000 mg
|
| Solution | Subcutaneous |
300 mg / 2 mL
|
| Solution | Subcutaneous |
300.000 mg
|
| Solution | Subcutaneous |
75 mg / 0.5 mL
|
| Injection, powder, for solution | Subcutaneous |
150 mg
|
| Injection, solution | Subcutaneous |
300.0 mg/2ml
|
| Injection, solution | Subcutaneous |
150 mg/ml
|
| Injection, solution | Subcutaneous |
75.0 mg/0.5ml
|
| Injection, powder, for solution | Cutaneous |
150 mg
|
| Injection, powder, for solution | Subcutaneous |
|
| Solution | Subcutaneous |
300 mg/2ml
|
| Injection, powder, for solution | Subcutaneous |
150 mg/1vial
|
| Injection, powder, lyophilized, for solution | Subcutaneous |
150 mg
|
| Injection, solution | — |
150 mg/1ml
|